| Pathway
|
Androgen Receptor to SGK1 Signaling in Prostate Cancer
|
|
Androgen Receptor to Akt Signaling in Prostate Cancer
|
|
Prostate Cancer Overview
|
|
Metastatic Colorectal Cancer Overview
|
|
Myostatin-IGF1 Crosstalk in Skeletal Muscles
|
|
IL6 in Insulin Resistance
|
|
Dystrophin Glycoprotein Complex Signaling in Duchenne Muscular Dystrophy
|
|
Ca2+ Overload in Duchenne Muscular Dystrophy
|
|
Duchenne Muscular Dystrophy Overview
|
|
IGF1 in Muscle Hypertrophy
|
|
RARA Signaling Pathway in Acute Myeloid Leukemia (M3)
|
|
FLT3 and KIT Signaling to MLL Pathway in Acute Myeloid Leukemia (M5)
|
|
Block of Apoptosis in Acute Myeloid Leukemia
|
|
Acute Myeloid Leukemia Overview
|
|
IL-6/IGF-1/VEGFA in Multiple Myeloma
|
|
Osteoclast Activation in Multiple Myeloma
|
|
Multiple Myeloma Overview
|
|
Chronic Myeloid Leukemia Overview
|
|
B-cell Acute Lymphoblastic Leukemia Overview
|
|
T-cell Acute Lymphoblastic Leukemia Overview
|
|
B-cell Chronic Lymphocytic Leukemia Overview
|
|
Glutamate in Parkinson's Disease
|
|
Hodgkin Lymphoma Overview
|
|
Diffuse Large-B-cell Lymphoma, ABC Subtype
|
|
Diffuse Large-B-cell Lymphoma, GCB Subtype
|
|
Diffuse Large-B-cell Lymphoma Overview
|
|
Follicular Lymphoma Overview
|
|
Cowden Syndrome
|
|
Dendritic Cells in Psoriasis
|
|
IFN-gamma/TNF-alpha Mediated anti-Apoptotic Effect in Psoriatic Keratinocytes
|
|
Interleukin-22 Induced Keratinocyte Proliferation in Psoriasis
|
|
Mantle Cell Lymphoma Overview
|
|
PI3K/AKT/MTOR, NF-kB and BCR Signaling Deregulation in Mantle Cell Lymphoma
|
|
Hedgehog Signaling in Mantle Cell Lymphoma
|
|
Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Overview
|
|
Proteins Involved in Pathogenesis of Breast Cancer Related to ERBB2/VEGFR/Akt Signaling Pathway
|
|
Proteins Involved in Pathogenesis of Breast Cancer Related to IGF1R/Akt Signaling Pathway
|
|
Breast Cancer Related to IGF1R/Akt Signaling Pathway
|
|
Breast Cancer Related to ERBB/VEGFR/Akt Signaling Pathway
|
|
Breast Cancer Related to ESR1 Signaling Pathway
|
|
Proteins Involved in Pathogenesis of Breast Cancer Related to ESR1 Signaling Pathway
|
|
ESR1/ERBB-positive Luminal Breast Cancer
|
|
Basal Breast Cancer
|
|
Activation of nNOS (NOS1) and iNOS (NOS2) via Glutamate in Familial Hemiplegic Migraine
|
|
Proliferative Diabetic Retinopathy
|
|
Insulin Influence on Glycogenesis
|
|
Insulin Influence on Protein Synthesis
|
|
Role of Advanced Glycation End Products Pathway in Diabetic Microangiopathy
|
|
Peripheral Tissue Microangiopathy in Insulin Resistance
|
|
Congenital Secondary (Central) Hypothyroidism
|
|
Congenital Hypothyroidism Due to Thyroid-Stimulating Hormone Resistance
|
|
Graves Ophthalmopathy
|
|
Thyroid Dysfunction in Graves Disease
|
|
Cardiovascular Effects of Hyperthyroidism
|
|
Common Non-genomic Effects of Thyroid Hormones
|
|
Effects of Hyperthyroidism on Bone Remodeling
|
|
Immune System Activation in Graves Disease Overview
|
|
Primary Overt Hypothyroidism Overview
|
|
Overt Hypothyroidism Influence on Thyroid-Stimulating Hormone Secretion
|
|
Clear Cell Ovarian Carcinoma
|
|
Mucinous Ovarian Carcinoma
|
|
High-grade Serous Ovarian Carcinoma
|
|
Endometrioid Ovarian Carcinoma
|
|
Ovarian Cancer Overview
|
|
Low-grade Serous Ovarian Carcinoma
|
|
Type I Endometrial Cancer (Endometrioid Endometrial Cancer)
|
|
Type II Endometrial Cancer (Clear-cell Endometrial Cancer and Papillary Serous Endometrial Cancer)
|
|
Endometrial Cancer Overview
|
|
Deregulation of Cell Cycle in Melanoma
|
|
Block of Apoptosis in Melanoma
|
|
MITF as a Regulator of Melanoma Cell Development
|
|
Dedifferentiation and Metastatic Progression of Melanoma
|
|
Proteins Involved in Pathogenesis of Melanoma
|
|
Melanoma Overview
|
|
Th1 Cell Function in Systemic Lupus Erythematosus
|
|
Th2 Cell Function in Systemic Lupus Erythematosus
|
|
B-cell Activation in Systemic Lupus Erythematosus
|
|
Th0 Cell Aberrant Activation in Systemic Lupus Erythematosus
|
|
T-cell-Dependent B-cell Activation
|
|
T-cell-Independent B-cell Activation
|
|
Natural Killer Cell Activation through C-type Lectin-like Receptors
|
|
Natural Killer Cell Activation through ITSM-Containing Receptors
|
|
Natural Killer Cell Activation through ITAM-Containing Receptors
|
|
Toll-like Receptors Act through MYD88-TIRAP Signaling
|
|
Central T-cell Tolerance
|
|
Peripheral T-cell Tolerance Overview
|
|
Model of T-cell Maturation
|
|
T-cell Positive Selection and Neglect-Induced Death
|
|
CD8+ T-cell Activation
|
|
Th17 Cell Differentiation
|
|
Th1 Cell Differentiation
|
|
T-cell Receptor Signaling
|
|
Regulatory T-cell Differentiation
|
|
Th2 Cell Differentiation
|
|
Cancer Overview
|
|
Necrosis of Neurons Caused by Energy Deficiency in Late Vasospasm
|
|
NO Synthesis in Early Vasospasm
|
|
Contraction due Vasospasm
|
|
Activation and Proliferation of Th1 Cells in Atherosclerosis
|
|
RAGE/AGER and S100 Proteins in Cardiovascular Injury in Atherosclerosis
|
|
Onset of Atopic Dermatitis
|
|
Smooth Muscle Cell Dysfunction in Pulmonary Arterial Hypertension
|
|
Primary Glioblastoma
|
|
Secondary Glioblastoma
|
|
Activation of Glioma Stem Cell Program
|
|
Glioma Invasion Signaling
|
|
Ependymoma
|
|
Astrocytoma
|
|
Medulloblastoma Overview
|
|
Block of CD4+ T-cell Signaling in HIV Type 1 Infection
|
|
Macrophage Survival through CCR5 and CXCR4 Mediated Signaling in HIV Type 1 Infection
|
|
Osteoarthritis Overview
|
|
Steroid-Induced Cataract
|
|
Growth Factor Signaling in Neuroblastoma
|
|
ALK-Associated Neuroblastoma
|
|
Neuroblastoma Overview
|
|
Growth Factor Signaling in Pancreatic Cancer
|
|
STK11 Signaling in Pancreatic Cancer
|
|
Pancreatic Ductal Carcinoma
|
|
Pancreatic Neuroendocrine Tumors
|
|
Impaired SHBG and IGFBP1 Synthesis in Polycystic Ovary Syndrome
|
|
FSH Action in Polycystic Ovary Syndrome
|
|
Block of Ovulation in Polycystic Ovary Syndrome
|
|
Polycystic Ovary Syndrome Overview
|
|
Peutz-Jeghers Syndrome Overview
|
|
Growth Factor Signaling in Hepatocellular Carcinoma
|
|
Hepatocellular Carcinoma Overview
|
|
Glutamate-Mediated Excitotoxicity in Amyotrophic Lateral Sclerosis
|
|
Impairment of Microglia Inhibition by Motor Neuron in Amyotrophic Lateral Sclerosis
|
|
Effects of BDNF Upregulation Induced by Seizures
|
|
Epilepsies Associated with Blood-Brain Barrier Disruption
|
|
mTOR Hyperactivation after Status Epilepticus
|
|
Proposed Mechanisms of Antiepileptic Effects of a Ketogenic Diet
|
|
Regulation of Vascular Reactivity in Raynaud Disease
|
|
B-cells Function in Systemic Scleroderma
|
|
Role of Th2 cells in Systemic Scleroderma
|
|
Proteins Involved in Pathogenesis of Myocardial Ischemia
|
|
Myocardial Remodeling in Myocardial Ischemia
|
|
Preconditioning Ischemia
|
|
Myocardial Infarction
|
|
BDKRB1/2 -> interleukins production
|
|
BDKRB1/2 -> vasodilation
|
|
PTGER2/3 -> vascular motility
|
|
HTR5 -> TNF production
|
|
HTR1 -> IL6 production
|
|
HTR1 -> membrane transport
|
|
CNR1/2 -> membrane transport
|
|
CNR1/2 -> IL1B/2/4/6/10 production
|
|
DRD2 -> TRPC1 transcription
|
|
DRD2/4 -> membrane transport
|
|
Nociception-related DRD2 expression targets
|
|
CHRM1/2/3/5 -> ion channels
|
|
CHRM1 -> IL2 production
|
|
TACR1 -> TNF/IL6/IL8 production
|
|
NPY1R -> CRH/POMC production
|
|
Nociception-related NTSR1 expression targets
|
|
NTRK1/2/3 -> acetylcholine production
|
|
GALR1/2/3 -> POMC/NPY production
|
|
Leptin -> NO production/vasodilation
|
|
GFs/TNF -> ion channels
|
|
Regulation of potassium flux
|
|
Regulation of sodium flux
|
|
Summarized nociception-related expression targets
|
|
Summarized vascular motility pathway
|
|
Regulation of calcium flux
|
|
FGFR -> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling
|
|
PDGFR -> AP-1/MYC signaling
|
|
PDGFR -> FOXO3A signaling
|
|
VEGFR -> AP-1/CREB/MYC signaling
|
|
VEGFR -> FOXO3A signaling
|
|
HGFR -> AP-1/CREB/MYC signaling
|
|
HGFR -> FOXO3A signaling
|
|
AngiopoietinR -> AP-1 signaling
|
|
ErythropoietinR -> AP-1/CREB/MYC signaling
|
|
ErythropoietinR -> FOXO3A signaling
|
|
ThrombopoietinR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> AP-1/CREB/ELK-SRF/MYC signaling
|
|
EGFR -> NCOR2 signaling
|
|
TNFRSF5/13B -> NFATC1 signaling
|
|
Notch -> NF-kB signaling
|
|
FcIgER -> ELK-SRF signaling
|
|
TLR1/2/6 -> NF-kB signaling
|
|
AGER -> NF-kB signaling
|
|
EGFR/ERBB2 -> HIF1A signaling
|
|
EGFR -> AP-1/ATF2 signaling
|
|
EGFR/ERBB2 -> TP53 signaling
|
|
EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ERBB2/3 -> EP300/ETS/ETV/SP1 signaling
|
|
KIT -> MITF signaling
|
|
VEGFR -> CTNNB signaling
|
|
InsulinR -> CTNNB/FOXA/FOXO signaling
|
|
InsulinR -> ELK-SRF/SREBF signaling
|
|
IGF1R -> CEBPA/FOXO1A signaling
|
|
IGF1R -> MEF/MYOD/MYOG signaling
|
|
GDNF -> HSF1 signaling
|
|
AngiopoietinR -> FOXO signaling
|
|
NTRK -> FOXO/MYCN signaling
|
|
NTRK -> AP-1/CREB/ELK-SRF/MYC/SMAD3/TP53 signaling
|
|
UrokinaseR -> ELK-SRF signaling
|
|
MacrophageR -> CEBPB/NF-kB signaling
|
|
FibronectinR -> CTNNB signaling
|
|
ICAM2 -> CTNNB/FOXO/STAT3 signaling
|
|
FibronectinR -> NF-kB signaling
|
|
FibronectinR -> AP-1/ELK-SRF/SREBF signaling
|
|
CD19 -> NF-kB signaling
|
|
IL7R -> FOXO/NF-kB signaling
|
|
IL12R -> NF-kB/NFATC signaling
|
|
IL15R -> NF-kB/NFATC signaling
|
|
IL4R -> ELK-SRF/HMGY signaling
|
|
IL2R -> ELK-SRF/MYC signaling
|
|
ErythropoietinR -> ELK-SRF/FOS signaling
|
|
ThrombopoietinR -> SPI1 signaling
|
|
ErythropoietinR -> NF-kB signaling
|
|
GHR -> ELK-SRF/MYC signaling
|
|
GHR -> NF-kB signaling
|
|
EDG2 -> ELK-SRF signaling
|
|
CholinergicRm -> CREB/ELK-SRF signaling
|
|
CannabinoidR -> AP-1/EGR signaling
|
|
NeuropeptideYR -> ATF/CREB signaling
|
|
DopamineR2 -> AP-1/CREB/ELK-SRF signaling
|
|
SerotoninR1 -> FOS signaling
|
|
DopamineR2 -> NF-kB signaling
|
|
PTAFR -> AP-1/ATF1/CREB/ERK-SRF signaling
|
|
VasopressinR1 -> MEF/MYOD/NFATC/MYOG signaling
|
|
PTAFR -> NF-kB signaling
|
|
AdenosineR -> NF-kB signaling
|
|
NeurotensinR -> ELK-SRF/AP-1/EGR signaling
|
|
VasopressinR1 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
AdrenergicRb -> STAT3 signaling
|
|
VasopressinR2 -> CREB/ELK-SRF/AP-1/EGR signaling
|
|
FSHR -> FOXO1A signaling
|
|
VasopressinR2 -> MEF/MYOD/NFATC/MYOG signaling
|
|
ThrombinR -> NF-kB signaling
|
|
ThrombinR -> AP-1/CREB/ELK-SRF/SP1 signaling
|
|
CD38 -> NF-kB signaling
|
|
Dexamethasone-Induced Diabetes
|
|
Doxorubicin-Induced Cardiotoxicity
|
|
Cytosolic Calcium Overload
|
|
Clozapine-Induced Granulocytopenia
|
|
Glutamate-Mediated Excitotoxicity
|
|
Tamoxifen-Induced Endometrial Cancer
|
|
Ritonavir-Induced Diabetes
|
|
ROS in Angiotensin-Mediated Cardiovascular Remodeling and Hypertrophy
|
|
TLR1/2/6 Expression Targets
|
|
NGF/FOXO/MYCN/ELK-SRF Expression Targets
|
|
BDNF Expression Targets
|
|
NTF3 Expression Targets
|
|
NTF4 Expression Targets
|
|
DLL1 Expression Targets
|
|
DLL4 Expression Targets
|
|
ADAM17 Expression Targets
|
|
CD40LG/NF-kB/ELK-SRF/CREB/NFATC Expression Targets
|
|
JAG1 Expression Targets
|
|
TNFSF13B Expression Targets
|
|
NGF/AP-1/TP53/MYC Expression Targets
|
|
NGF/CREB/CEBPB/MEF2A Expression Targets
|
|
NGF/SMAD3/NF-kB Expression Targets
|
|
ICAM1 Expression Targets
|
|
Fibrinogen Expression Targets
|
|
Fibronectin Expression Targets
|
|
CD21 Expression Targets
|
|
CD247 Expression Targets
|
|
FCGR3A Expression Targets
|
|
PECAM1 Expression Targets
|
|
PLAU/ELK-SRF/AP-1 Expression Targets
|
|
CD19 Expression Targets
|
|
CD81 Expression Targets
|
|
IL12B Expression Targets
|
|
IL15 Expression Targets
|
|
IL7 Expression Targets
|
|
IL2 Expression Targets
|
|
IL4 Expression Targets
|
|
Thrombopoietin/SPI1 Expression Targets
|
|
Erythropoietin/ELK-SRF Expression Targets
|
|
Erythropoietin/NF-kB Expression Targets
|
|
GH1-GHR/NF-kB/ELK-SRF/MYC Expression Targets
|
|
PRL-GHR/NF-kB/ELK-SRF/MYC Expression Targets
|
|
CSH1-GHR Expression Targets
|
|
NPY Expression Targets
|
|
Dopamine/Gi Expression Targets
|
|
Dronabinol/Anandamide Expression Targets
|
|
S100B Expression Targets
|
|
S100P Expression Target
|
|
HMGB1 Expression Targets
|
|
TTR Expression Targets
|
|
Acetylcholine Expression Targets
|
|
AREG/AP-1 Expression Targets
|
|
AREG/HIF1A Expression Targets
|
|
AREG/NFATC Expression Target
|
|
BTC/EP300/ETS/ETV/SP1 Expression Targets
|
|
BTC/NFATC Expression Targets
|
|
EGF/HIF1A Expression Targets
|
|
EGF/TP53 Expression Targets
|
|
EREG/AP-1/ATF Expression Targets
|
|
EREG/EP300/SP1 Expression Targets
|
|
EREG/HIF1A Expression Target
|
|
HBEGF/AP-1/ATF Expression Targets
|
|
HBEGF/EP300/ETS/ETV/SP1 Expression Targets
|
|
HBEGF/HIF1A Expression Targets
|
|
HBEGF/MEF/MYOD Expression Target
|
|
HBEGF/TP53 Expression Targets
|
|
NRG1/AP-1/ATF Expression Targets
|
|
NRG1/EP300/ETS/ETV/SP1 Expression Targets
|
|
NRG1/HIF1A Expression Target
|
|
NRG1/MEF/MYOD Expression Targets
|
|
NRG1/TP53 Expression Target
|
|
TGFA/HIF1A Expression Targets
|
|
TGFA/MEF/MYOD/NFATC Expression Targets
|
|
TGFA/TP53 Expression Targets
|
|
VEGFA/CTNNB/CTNND Expression Targets
|
|
VEGFC/CTNNB Expression Target
|
|
GDNF/HSF1 Expression Targets
|
|
IGF2/CEBPA/FOXO1A Expression Targets
|
|
IGF2/MEF/MYOD Expression Targets
|
|
CTGF/AP-1/CREB/MYC Expression Targets
|
|
CTGF/FOXO3A Expression Target
|
|
CTGF/NCOR2 Expression Target
|
|
Erythropoietin/AP-1/MYC/CREB Expression Targets
|
|
Erythropoietin/FOXO3A Expression Targets
|
|
GAS6/AP-1/CREB Expression Targets
|
|
PGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Thrombopoietin/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
Thrombopoietin/FOXO3A Expression Target
|
|
AREG/CREB/CREBBP Expression Targets
|
|
AREG/FOXO3A Expression Target
|
|
AREG/NCOR2 Expression Targets
|
|
EGF/FOXO3A Expression Targets
|
|
EGF/NCOR2 Expression Target
|
|
EREG/CREB Expression Target
|
|
EREG/FOXO3A Expression Target
|
|
HBEGF/CREB/MYC Expression Targets
|
|
HBEGF/FOXO3A Expression Target
|
|
NRG1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
NRG1/FOXO3A Expression Targets
|
|
TGFA/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
TGFA/FOXO3A Expression Targets
|
|
FGF1/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
FGF1/NCOR2 Expression Target
|
|
FGF2/FOXO3A Expression Targets
|
|
FGF2/NCOR2 Expression Targets
|
|
FGF4/AP-1/MYC Expression Targets
|
|
FGF7/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF7/FOXO3A Expression Target
|
|
FGF8/AP-1/CREB/MYC Expression Targets
|
|
FGF9/AP-1/CREB/MYC Expression Targets
|
|
FGF10/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
FGF10/FOXO3A Expression Target
|
|
FGF18/AP-1/CREB Expression Targets
|
|
FGF23/NCOR2 Expression Targets
|
|
CSF1/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
CSF1/FOXO3A Expression Targets
|
|
PDGFB/AP-1/CREB/MYC Expression Target
|
|
PDGFB/FOXO3A Expression Target
|
|
PDGFC/CREB Expression Target
|
|
PDGFD/AP-1 Expression Targets
|
|
VEGFA/FOXO3A Expression Targets
|
|
VEGFA/NCOR2 Expression Target
|
|
HGF/FOXO3A Expression Targets
|
|
ANGPT1/CREB/CREBBP Expression Targets
|
|
ANGPT2/AP-1/CREBBP/MYC Expression Targets
|
|
FIGF/AP-1 Expression Target
|
|
FIGF/NCOR2 Expression Target
|
|
PDGF/FOXO3A Expression Targets
|
|
F2 -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
F2 -> STAT1/NF-kB Expression Targets
|
|
PLG -> AP-1/CREB/ELK-SRF/SP1 Expression Targets
|
|
PLG -> STAT1/NF-kB Expression Targets
|
|
Adenosine Expression Targets
|
|
AVP/Gq -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gq -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
PAF/Gq -> NF-kB Expression Targets
|
|
NTS Expression Targets
|
|
Epinephrine/Gs Expression Targets
|
|
Noradrenaline/Gs Expression Targets
|
|
FSHR Expression Targets
|
|
AVP/Gs -> MEF/MYOD/NFATC/MYOG Expression Targets
|
|
AVP/Gs -> CREB/ELK-SRF/AP-1/EGR Expression Targets
|
|
FGF2/AP-1/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
IGF1/CEBPA/FOXO1A Expression Targets
|
|
Insulin/ELK-SRF/HIF1A/MYC/SREBF Expression Targets
|
|
NOTCH Expression Targets
|
|
EGF/AP-1/ATF Expression Targets
|
|
EGF/CREB/CREBBP/ELK-SRF/MYC Expression Targets
|
|
EGF/MEF/MYOD/NFATC Expression Targets
|
|
HGF/AP-1/CREB/ELK-SRF/MYC Expression Targets
|
|
IGF1/MEF/MYOD/MYOG Expression Targets
|
|
Insulin/CEBPA/CTNNB/FOXA/FOXO Expression Targets
|
|
Insulin/MEF/MYOD Expression Targets
|
|
KITLG/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
LPA Expression Targets
|
|
PAF/Gq -> AP-1/ATF1/CREB/ERK-SRF Expression Targets
|
|
PDGF/AP-1/CREB/CREBBP/MYC Expression Targets
|
|
TGFA/AP-1/ATF Expression Targets
|
|
VEGFA/AP-1/CREBBP/MYC Expression Targets
|
|
BTC/AP-1/ATF/CREB Expression Targets
|
|
protein kinase C (PKC) signaling pathway
|
|
phosphatidylinositol 3-kinase-Akt signaling pathway
|
|
phosphatidylinositol 3-kinase-Akt signaling pathway
|
|
phosphatidylinositol 3-kinase-Akt signaling pathway
|